Market research
4GB.F Gossamer Bio, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 804K
- P/E ratio
- Not available
- Analyst target
- 19.38
- Dividend yield
- Not available
- Beta
- 2.0
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US38341P1021
- Market cap
- 804K
- P/E ratio
- Not available
- Analyst target
- 19.38
- Dividend yield
- Not available
- Beta
- 2.0
About
About Gossamer Bio, Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4GB.F discussion.
5 years, 5 months ago
Gossamer Bio, Inc is currently in a long term downtrend where the price is trading 15.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Gossamer Bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 18.1% to $-65M since the same quarter in the previous year.
Finally, its free cash flow grew by 20.1% to $-37M since the same quarter in the previous year.
Based on the above factors, Gossamer Bio, Inc gets an overall score of 2/5.